体检发现的218例肿瘤病人细胞质胸苷激酶1在临床应用中的分析与研究  

Clinical application of cytosolic thymidine kinase 1 in 218 cases with tumor

作　　者：王朝敏[1] 徐道亮[2] 李斌[3] 

机构地区：[1]江苏省苏北人民医院肿瘤科,江苏扬州225001 [2]江苏省苏北人民医院内科,江苏扬州225001 [3]江苏省苏北人民医院核医学科,江苏扬州225001

出　　处：《云南医药》2012年第6期516-518,共3页Medicine and Pharmacy of Yunnan

摘　　要：目的探讨肿瘤患者血清细胞质胸苷激酶(TK1)在临床应用上的意义。方法利用免疫印迹增强化学发光法,检测218例肿瘤患者血清和40例健康体检者血清的TK1水平。结果肿瘤病人TK1阳性率为45.29%,健康体检者血清TK1阳性率为5%。鳞癌TK1阳性率为26.09%,腺癌TK1阳性率为54.29%。其中乳腺肿瘤、消化道肿瘤、其它肿瘤TK1阳性率较高,分别达55.57%、62.51%、53.86%。肺部肿瘤及宫颈肿瘤的TK1阳性率较低,分别为12.51%、14.3%。结论血清TK1检测在腺癌的辅助诊断上是一个有价值的标志物。Objective To investigate the clinical significance of cytosolic thymidine kinase （TK1） in tumor pa- tients .Methods Using immunoblotting enhanced chemiluminescence to detect serum TK1 levels in 218 cancer pa- tients and 40 healthy cases. Results The positive rate of TK1 in tumor patients was 45.29%,and in healthy subjects the positive rate was 5%. In squamous cell carcinoma,the positive rate was 26.09% and the positive rate was 54.29% in adenocarcinoma. In breast cancer, digesti 62.51% and 53.86% respectively. In lung 12.51% and 14.3%. Conclusion The TK1 ve tract tumor and other tumors the positive rates were higher, of 55.57%, cancer and cervical cancer, TK1 positive rates were low, respectively of in serum aids diagnosis for adenocarcinoma and is a valuable marker for

关 键 词：细胞质胸苷激酶1 肿瘤标志物 免疫印迹增强化学发光法 

分 类 号：R730.45[医药卫生—肿瘤]